Researchers from Monash University have developed a new drug delivery strategy able to block pain within the nerve cells, in what could be a major development of an immediate and long lasting treatment for pain.
More than 100 million Americans suffer from chronic pain and this figure is expected to grow, driven by the increased life expectancy, increasing incidence of diabetes and cancer, combined with better survival rates, often leaving patients with severe and poorly treated pain. The global market for nerve pain treatments is over US$600 billion and yet current pain therapies are not completely effective and often suffer from unwanted side effects.
Research published in the journal, Science Translational Medicine, reveals how a target protein, long known to be associated with both chronic and acute pain, works within the nerve cell. This protein is the NK1 receptor, the receptor of the neuropeptide substance P, which mediates pain transmission. Because of its association with pain and other diseases of the nervous system, many drug development attempts have focused on inhibiting this receptor, but the efficacy of these treatments has been very limited. This new work shows that such ineffectiveness could be in part because the treatments targeted the protein on the surface of the nerve cell.
Dr Michelle Halls and Dr Meritxell Canals from the Monash Institute of Pharmaceutical Sciences (MIPS) and the ARC Centre for Excellence in Bio-Nano Science (CBNS) at Monash University, have worked with Professor Nigel Bunnett, previously at Monash and now at Columbia University in the US, and Professor Chris Porter from MIPS and CBNS.
Together they have found that the NK-1 receptor controls pain once it is inside the cell — so drugs that merely block it when it is on the surface of the cell have little efficacy. Instead, this new research shows that, in animal models, if the NK-1 receptor is blocked once it enters the nerve cell, it is possible to suppress pain more effectively.
Dr Halls said that the new strategy of “targeting receptors inside the cell represents a new frontier in drug delivery and a novel therapeutic strategy for dealing with pain.”
Working with a multidisciplinary team of cell biologists, pharmacologists, physiologists and drug delivery experts, the researchers developed drugs that specifically target NK-1 receptors within the nerve cell. Animal studies showed that using the drugs — which have an engineered lipid attachment that targets the drug to the NK-1 receptor inside the cell, could block pain for extended periods in several animal models.
Dr Canals said: “This is a proof-of-concept study that shows that we can re-engineer current pain drugs and make them more effective. The challenge is now to translate the technology into human clinical trials. This is a complex and challenging path — but the ultimate benefits to patients with nerve pain are potentially highly significant.”
The Latest on: Pain relief
- Common joint pain treatment may be harmful: Studyon October 16, 2019 at 5:44 am
A frequently performed treatment for osteoarthritis and other joint related pain syndromes are intra-articular corticosteroid injections, yet there is conflicting evidence on their potential benefit.
- Common Joint Pain Treatment Dubbed ‘Unsafe’ By Expertson October 16, 2019 at 1:11 am
In the seven decades since, hundreds of millions of people around the world have had cortisone shots for short-term pain relief and to reduce the swelling from both rheumatoid arthritis and ...
- This common joint pain treatment may be harmful, study sayson October 15, 2019 at 1:05 pm
Researchers from Boston University School of Medicine recently conducted a study to explore the unintended effects of intra-articular corticosteroid injections, a common treatment for osteoarthritis ...
- Four new poetry collections bring pain — and hope — into sharp reliefon October 15, 2019 at 12:01 pm
“Some wounds cannot be hushed,” he notes. “The poem begins with pain as a mirror.” That mirror allows the speaker to consider both personal losses — the death of his mother, a lover leaving, a ...
- Common joint pain treatment may be more harmful than thoughton October 15, 2019 at 7:09 am
A common therapy for joint pain may not be as safe as experts believed, according to a new report published Tuesday. Corticosteroid injections are often given to reduce pain and inflammation from ...
via Google News and Bing News